Ligand Pharmaceuticals Inc (NAS:LGND)
$ 81.36 -1.01 (-1.23%) Market Cap: 1.46 Bil Enterprise Value: 1.16 Bil PE Ratio: 15.29 PB Ratio: 1.81 GF Score: 76/100

Ligand Pharmaceuticals Inc Announce Sale of Promacta Assets and Royalty to Royalty Pharma Call Transcript

Mar 05, 2019 / 10:00PM GMT
Release Date Price: $75.21 (-1.70%)
Operator

It is now my pleasure to turn today's program over to Todd Pettingill, Senior Director, Corporate Development and Investor Relations. The floor is yours.

Todd Pettingill
Ligand Pharmaceuticals Incorporated - Director of Corporate Development

Welcome to today's conference call to discuss Ligand's sale of Promacta royalty to Royalty Pharma. Speaking today for Ligand are John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO.

As a reminder, today's call will contain forward-looking statements within the meaning of federal securities laws. These may include, but are not limited to statements regarding intent, belief or current expectations of the company and its management regarding its internal and partnered programs. These statements involve risks and uncertainties, and actual events or results may differ materially from the projections described in today's press release and this conference call. Additional information concerning risk factors and other matters concerning Ligand can be found in Ligand's earnings press release and public periodic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot